More NewsRead More
Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
April 15, 2016
Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics
March 31, 2016
from PR Newswire
from Market News Video
Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
April 06, 2016
BRIEF-Incyte Corp says EVP Richard Levy to retire
April 18, 2016
from Blogs - TalkMarkets
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here